10:48 a.m.
US Stock Market - Stock Profile of the Week
Symbol: HTDS
Market: PK
Sector: MEDICAL RESEARCH
BARCHART Rates HTDS an 80% BUY - http://quotes.barchart.com/texpert.asp?sym=HTDS
Before we begin our profile we have very exciting, breaking news...
Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials
BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Diseases Incorporated
(Pink Sheets:HTDS) announces that Tubercin® has passed the toxicity tests required to
proceed to the live cancer trials. Testing Tubercin® on live Melanoma, Lung and Breast
cancer cells will begin immediately. The President and CEO, Mr. Colm J. King, met with
the spokesperson of the medical group at their offices in Oklahoma City. Mr. King was
advised that the tests were conducted under strict FDA (Federal Drug Administration)
guidelines. Full test results will be available at the corporate offices as soon as the
reports and findings are printed.
"These are the most promising results to date regarding Tubercin® and we're
looking forward to additional positive results in the near future," stated Mr. King.
"These tests prove that Tubercin® is non-toxic and is the first step on the way to
human clinical trials as well as the first positive breakthrough conducted in the United
States with an independent medical group for Tubercin®."
Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated
("HTTD") holds the international marketing rights, except South Korea, to
Tubercin®, a patented immunostimulant developed for combating Cancer under medical patent
(US Patent 6,274,356). The unique properties unlike other cancer products are clearly
stated in the abstract summary of the patent... "A carbohydrate complex, which is a
mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted
from Mycobacterium tuberculosis, is highly effective in treating various cancer patients
without incurring any adverse side effects."
STOCK PROFILE OF THE WEEK
HTDS is now at an emerging and potentially explosive stage. As stated in their press
release, Tubercin is now ready to proceed (after tests conducted under strict FDA
guidelines) to human clinical trials. While they have jumped one very big hurdle, they
are still in the early stages of development and now is a great time for investors to take
heed.
TUBERCIN
Over the past ten years, epoch making anticancer agents have continuously been introduced,
but the mortality of cancer patients have been rising in the U.S. and the European
countries not to mention Japan and Korea. The decisive measure to cope with cancer is
surgery.
When the cancer cells spread throughout the body instead of remaining on the original
spot, the treatment should take into consideration chemotherapy, radiation therapy and
immunotherapy. The drawback of such therapies, however, is they incur damages not only on
cancer cells, but also on the normal cells.
Chemotherapy and radiation therapy are not suitable for application on weakened patients,
especially those above 70. Historically, various forms of immunotherapy have been
performed, falling short of therapeutic expectation. When Bacille calmetteguerin is used
as an active no-specific immunotherapeutic agent, however, the patient's prognosis
turns better through a simulative action on immune system of the cancer case.
Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from microbacterium
tuberculosis to be used as immunostimulant. This was meant to activate the T-lymphocyte of
the cancer patient to produce lymphokine. This process strengthened and promoted immuno
surveillance activities in deficient state and alleviated the pain and prolonged the life
of cancer patients.
Of late the pharmaceutical industry in advanced countries started to put on the market so
called cancer vaccines (active specific immunotherapy). The vaccines, bacterial extracts,
as adjuvants, with autologous and or allogenic cancer cells to generate antibodies to
cancer cells, facilitating the killer T-cells to recognize and destroy cancer cells.
The laboratory work to modify autologous or allogenic cancer cells are not ordinary and
simple. When our lab work augments the active specific immunotherapeutic agents, the
Tubercin will be one of the best adjuvants. Meanwhile, the main point of AIDS is its virus
killing T-cells and Tubercin helps maintain healthy T-cells. Consequently, we focus our
effort on the application of Tubercin to AIDS.
TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant, TUBERCIN
strengthens the human body's own immune system and assists the body in seeking out and
combating cancer cells. HTTD is potentially able to develop TUBERCIN into a low-cost
product to treat cancer patients on an international scale. Salient treatment, through the
administration of TUBERCIN, could positively affect thousands of lives in North America.
In addition, Europe and Asia have millions of lives at risk each year because of viral
diseases such as cancer.
TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered to
human patients in stages three and four of terminal cancer. There have been no indications
of any adverse side effects in human trials. There has been encouraging results of
patients with TUBERCIN in the last fourteen years. Various forms of cancer were involved
and many of the patients survived.
A review of clinical studies indicate TUBERCIN has no side effects and could possibly be
administered in conjunction with other such modalities for the treatment of cancer without
any adverse effects. The scientific presumption would be the distinct possibility of a
strengthened immunity system and the administration of treatment such as chemotherapy at
the later stages of tumor growth would not be impeded by the weakened condition of the
terminal cancer patient. To this end the Company has been assisted by outside consultants
reviewing the research data and human trials involving TUBERCIN to see specifically
whereby incidents of dual treatment produced favorable results in terms of moving toward
indication of prolongation of the life of the cancer patient.
There is recognition that morphine is an trusted pain killer, but in totality it cannot be
said that it has no side effects. In the maintaining of patient care, there is the strong
possibility that TUBERCIN could be also considered as a candidate for a pain management.
The Company's scientists describe TUBERCIN as having the high propensity of deadening
the nerve endings in specific areas of the body where cancer has caused erosion and
consequently much pain.
PATENTS
Presently, HTTD has the patent rights for Korea, Japan and the United States. The Korean
patent was issued on October 29, 1998 (Registration No. 173362). The Japanese patent was
issued on June 12, 1998 (Registration No. 2790447). The United States patent was issued on
August 14, 2001 (Registration No.6,274,356). Currently, patents are pending for Canada and
Europe (the United Kingdom, France, Germany, Italy and Spain).
CANCER IN OUR TIME
In the 20th century, the number of cancer patients has been on the increase. Although many
anti-cancer agents were developed and an enormous study on its essence continued, the
mortality by cancer still is increasing. Mankind may be chronically threatened with cancer
in the 21st century. Nine million new case of cancer occur annually and five million
people die from breast cancer, reports the World Health Organization. Dramatic increases
in life expectancy and change in lifestyle are estimated to increase the number of new
cancer cases to 20 million annually by 2020 and cancer deaths to more than 10 million.
About 552,200 Americans - more than 1,500 people a day - are excepted to die of cancer
this year. In the United States, one of every four deaths is attributed to cancer. Cancer
is the second-leading cause of death in the United States. Exceeded only by heart disease.
About 5 million lives have been lost to cancer since 1990 and about 13 million new cases
have been diagnosed. In 2000, more then 1.2 million new cancer cases are expected to be
diagnosed. The number of cancer cases will continue to grow, spurred by the aging
population. By 2009, this patient group could total 8.4 million. In 1997, about 6.3
million people worldwide died from some form of cancer, and most major international
cancer agencies expect this number to double by 2022.
Please note that HTDS had absolutley nothing to do with this report and is not a
participant in any way.
No more advertisements: http://doubleopt.biz/optout.html
Stock Market Today is an independent research firm. This report is based on Stock Market
Today's independent analysis but also relies on information supplied by sources
believed to be reliable. This report may not be the opinion of HTDS management. Stock
Market Today has also been retained to research and issue reports on HTDS. Stock Market
Today may from time to time purchase or sell HTDS common shares in the open market without
notice. The information contained in this report shall not constitute, an offer to sell or
solicitation of any offer to purchase any security. It is intended for information only.
Some statements may contain so-called "forward-looking statements". Many factors
could cause actual results to differ. Investors should consult with their Investment
Advisor concerning HTDS. Copyright 2003 © Stock Market Today Ltd. All Rights Reserved.
This newsletter was distributed by MMS, Inc. MMS was paid eight hundred and fifty thousand
shares HTDS stock to distribute this report. MMS is not affiiated with Stock Market Today
and is not responsible for newsletter content.
unhugxjy zfjndnhs esyd qwks